Skip to main content
Premium Trial:

Request an Annual Quote

Diversa, Glaxo Wellcome Pen Deal to Jointly Research Molecules

NEW YORK, Dec 12 - Diversa said Tuesday it had reached an agreement with Glaxo Wellcome to jointly research novel small molecules in Diversa’s PathwayLibraries.

Under the terms of the non-exclusive deal, Diversa and Glaxo Research and Development, a subsidiary of Glaxo Wellcome, will identify and screen molecules in the database for specific pharmaceutical activity.

Glaxo Wellcome will receive exclusive worldwide rights to molecules selected for commercialization. Diversa did not disclose financial terms of the deal.

Diversa's PathwayLibraries holds small molecule drug candidates produced by collections of gene pathways from environmental sources. Complex recombinant libraries are generated from uncultivated microorganisms with the company’s own methods for extracting DNA from the environment and by applying patented normalization methodologies.

The company said that its approach helps to speed up drug discovery and to identify gene products from the many microbes that remain unexplored.

" This collaboration with Diversa gives Glaxo Wellcome the potential to evaluate a new source of chemical diversity with the potential to generate novel leads for important therapeutic targets," said Allan Baxter, group discovery director at Glaxo Wellcome, said in a statement.

Earlier this month, Diversa said it had signed a “multi-year, cross-royalty” collaboration with Celera to sequence the genomes of extremophiles in its libraries.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.